Drug Profile
Research programme: cardiac regeneration therapies - ChemRegen/Human BioMolecular Research Institute/Sanford-Burnham Medical Research Institute
Latest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator ChemRegen; Human BioMolecular Research Institute; Sanford Burnham Prebys Medical Discovery Institute
- Class Cell therapies; Heart failure therapies
- Mechanism of Action Wnt signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Heart failure
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for research development in Heart-failure in USA (Parenteral, Injection)
- 28 Aug 2018 No recent reports of development identified for research development in Heart-failure in USA (PO, Pill)
- 01 Aug 2016 Early research is underway in the US